Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year’s $2.68.
Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 billion and indicating a 9.8% increase year-over-year.
Completion of a $750 million share repurchase in fiscal year 2025, reflecting confidence in BD’s financial stability and future prospects.
Becton, Dickinson and Company, known as BD, trades on the NYSE:BDX. It is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD’s competitors include companies like Medtronic and Johnson & Johnson. The company focuses on improving medical discovery, diagnostics, and the delivery of care.
On February 6, 2025, BD reported earnings per share (EPS) of $3.43, surpassing the estimated $3. This strong performance is further highlighted by the Zacks Consensus Estimate, which was $2.98 per share. Compared to the same quarter last year, where EPS was $2.68, BD shows significant growth, reflecting its robust financial health and operational efficiency.
BD’s revenue for the first quarter of fiscal 2025 reached approximately $5.17 billion, exceeding the estimated $5.10 billion. The company achieved a 9.8% increase in revenue, with 9.6% being currency-neutral and 3.9% organic growth. This indicates BD’s ability to grow its business despite currency fluctuations, showcasing its strong market position and strategic execution.
The company has also completed a $750 million share repurchase in fiscal year 2025, demonstrating confidence in its financial stability and future prospects. BD’s price-to-earnings (P/E) ratio of 41.12 and price-to-sales ratio of 3.52 reflect the market’s positive valuation of its earnings and sales. The enterprise value to sales ratio of 4.43 and enterprise value to operating cash flow ratio of 23.56 provide insight into BD’s overall value and cash flow efficiency.
BD’s strategic initiatives, such as the BD 2025 strategy, aim to unlock significant value through the planned separation of Biosciences and Diagnostic Solutions. This move is expected to allow each entity to focus on maximizing growth and innovation. With a debt-to-equity ratio of 0.35 and a current ratio of 1.17, BD maintains a moderate level of debt and a solid ability to cover short-term liabilities, ensuring financial stability.
